Clinical Trial Update: Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer [Phase 1, Phase 2]

View source ↗

Summary

Scancell's Modi-1 Moditope is being studied in Phase 1/2 trials across several cancers, including triple-negative breast cancer, renal cell carcinoma, high-grad…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• High-grade Ovarian Serous Carcinoma
• Renal Cell Carcinoma
• Squamous Cell Carcinoma of the Head and Neck
• Triple-negative Breast Cancer

Drugs mentioned

• Modi-1 Moditope

Snippet

Sponsor: Scancell Ltd | Conditions: Triple Negative Breast Cancer, Renal Cell Cancer | Phase 1, Phase 2 | Status: RECRUITING